QIAGEN expands automated liquid biopsy portfolio to enhance oncology, prenatal care and organ transplant applications

QIAGEN announced updates to its sample technologies solutions for non-invasive liquid biopsy applications for use in research and clinical applications such as oncology, prenatal care and organ transplantation.

These updates – designed for use on the QIAsymphony and EZ2 Connect instruments – are designed to enable research and molecular diagnostics laboratories to efficiently improve results when processing larger sample volumes that are crucial for oncology research and diagnostics: 

• The upgraded EZ1&2 ccfDNA Kit now supports fully automated simultaneous processing of 24 samples with up to 10 mL of serum or plasma – up from the previous 8 mL – along with a new urine protocol. These enhancements are tailored for cancer research and biomarker discovery, providing higher yields of circulating cell-free DNA (ccfDNA) without manual pre-enrichment steps, and offering flexibility in downstream workflows with lower elution volumes and higher concentrations of ccfDNA.

• The newly introduced QIAsymphony DSP Circulating DNA Kit (96) and the QIAsymphony DSP Circulating DNA Maxi Kit (192) are fully automated kits, optimized for the extraction of ccfDNA from up to 10mL sample volume. The regular kit addresses labs which are only starting with liquid biopsy or have small sample numbers, while the Maxi Kit is tailored for labs which routinely work with liquid biopsy samples. Both kits are intended for in-vitro diagnostic (IVD) use, ensuring compliance with CE-IVDR regulations in Europe and FDA regulations in the U.S.

QIAGEN release